Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK. (September 2018)

• Record Type: Journal Article
• Authors: Bagshaw, Emma; Enoch, David A; Blackney, Michael; Posthumus, Jan; Kuessner, Daniel
• Is Part Of: Future microbiology. Volume 13:Number 11(2018)
• Page Start: 1283
• Page End: 1293
• Publication Date: 2018-09
• Subjects: aspergillosis -- cost -- economic -- healthcare -- invasive fungal infection -- invasive mold disease -- isavuconazole -- liposomal amphotericin B -- mucormycosis -- posaconazole; Microbiology -- Research -- Periodicals; 616.9041
• DOI: 10.2217/fmb-2018-0119
• Languages: English
• ISSNs: 1746-0913

Abstract

Aim: Invasive mold diseases (IMDs) are associated with significant morbidity and mortality. Approved treatments include voriconazole (VORI), liposomal amphotericin B (L-AMB), posaconazole (POSA) and isavuconazole (ISAV). A UK-based economic model was developed to explore the cost of treating IMDs with ISAV versus L-AMB followed by POSA.Materials & methods: As indirect comparisons have demonstrated similar efficacy between the comparators, a cost-minimization approach was taken. Drug acquisition, administration & monitoring, and hospitalization costs were evaluated from the healthcare system perspective.Results: Per-patient costs were UK£14, 842 with ISAV versus UK£18, 612 with L-AMB followed by POSA. Savings were driven by drug acquisition, and administration & monitoring costs.Conclusion: ISAV has the potential to reduce IMD treatment costs relative to L-AMB followed by POSA.